Malastad

Atovaquone/Proguanil, the active ingredient in Malastad, is an antimalarial presented as an oral tablet for systemic use. It is used to prevent malaria infection and to treat acute uncomplicated Plasmodium falciparum malaria in adults and children. GNH USA supplies Malastad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malastad belongs to the antimalarial drug class and is indicated for both prophylaxis and treatment of malaria caused by Plasmodium species. - Malaria prophylaxis: prevents infection in travelers to endemic regions. - Uncomplicated Plasmodium falciparum malaria: treats acute infection after it occurs. - Combination therapy: used with other antimalarials to reduce the risk of resistance and recurrence.

Adverse reactions may occur with Malastad and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Abdominal pain: cramp‑like discomfort. - Vomiting: occasional emesis. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Severe hypersensitivity: including anaphylaxis. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hemolytic anemia: breakdown of red blood cells. - Severe neutropenia: markedly reduced neutrophil count. - Acute renal failure: sudden loss of kidney function.

Before prescribing Malastad, consider patient‑specific factors and safety measures. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: caution advised; drug may be excreted in milk. - Renal impairment: assess kidney function and adjust if necessary. - Hepatic impairment: monitor liver enzymes during therapy. - Drug resistance: avoid using as monotherapy in areas with known resistance. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Malastad may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing atovaquone levels. - Phenobarbital: lowers plasma concentrations, compromising efficacy. - Protease inhibitor antiretrovirals: may increase toxicity risk.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., azithromycin): can raise atovaquone exposure. - Sulfonamides: additive risk of hypersensitivity reactions. - Warfarin: potential alteration of INR, requiring closer monitoring.